Health sciences company PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) stated on Wednesday that it plans to launch the clinical trials of its cannabinoid Sol-gel to reduce the possibility of contracting coronavirus infections.
In conjunction with the COVID-19 Sol-Gel clinical programme, the company has retained Veristat, a global clinical research organization (CRO) located in Massachusetts, USA, to assist with planning the clinical trial process and writing the required protocols.
Pursuant to the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical programme and required protocol.
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes